Wegovy vs Ozempic South Africa: Same Semaglutide, Different Purpose

Here is the question South African patients keep asking their doctors: "Should I get Wegovy or Ozempic?" The confusing part is that both contain exactly the same active ingredient — semaglutide, made by the same manufacturer (Novo Nordisk). So why do two products exist, and does it matter which one you use? This guide breaks down every meaningful difference for the South African market in 2026.

The short answer: Wegovy is registered specifically for chronic weight management. Ozempic is registered for type 2 diabetes. The active molecule is identical, but the maximum dose, titration schedule, and regulatory approval differ — and that affects what your medical aid covers and what your doctor prescribes.

Quick Comparison Table

Before we dive into the detail, here is the side-by-side overview:

Why Two Products for the Same Drug?

This confuses nearly everyone, so here is the simple explanation. Novo Nordisk originally developed semaglutide for type 2 diabetes and marketed it as Ozempic (approved in South Africa for diabetes management). Doctors quickly noticed that patients on Ozempic lost significant weight — more than with previous GLP-1 drugs like liraglutide (Saxenda).

Novo Nordisk then ran dedicated weight loss trials (the STEP programme) using semaglutide at a higher dose of 2.4 mg and got regulatory approval for weight management under the brand name Wegovy. Same molecule, higher ceiling dose, different label.

Think of it like paracetamol: Panado and Painblok contain the same ingredient, but the packaging, dose, and marketing differ.

The Dose Difference Matters

This is arguably the most important practical difference:

• Ozempic tops out at 2.0 mg per week. Most patients stabilise at 0.5 mg or 1.0 mg for blood sugar control.
• Wegovy goes up to 2.4 mg per week — a 20% higher maximum dose specifically calibrated for weight loss.

The STEP 1 trial showed that the 2.4 mg dose produced an average 14.9% body weight reduction over 68 weeks in people without diabetes. That extra 0.4 mg over Ozempic's ceiling matters when the goal is maximum fat loss rather than glycaemic control.

However, many South African doctors prescribe Ozempic off-label at 1.0 mg or 2.0 mg for weight loss — particularly when Wegovy stock is limited or when medical aid covers Ozempic but not Wegovy.

Titration Schedules: Wegovy Takes Longer to Ramp Up

Both drugs start at a low dose to let your body adjust and minimise nausea. But the titration paths differ:

Wegovy Titration (16 weeks)

• Weeks 1-4: 0.25 mg
• Weeks 5-8: 0.5 mg
• Weeks 9-12: 1.0 mg
• Weeks 13-16: 1.7 mg
• Week 17 onwards: 2.4 mg (maintenance)

Ozempic Titration (8 weeks)

• Weeks 1-4: 0.25 mg
• Weeks 5-8: 0.5 mg
• Week 9 onwards: 1.0 mg (may increase to 2.0 mg)

Wegovy's slower ramp-up means it takes about four months to reach the full weight-loss dose. This is deliberate — the higher ceiling dose requires a more gradual adjustment to reduce GI side effects. Be patient with the process.

Cost in South Africa (2026)

Neither drug is cheap. Here is what South Africans are paying out of pocket in 2026:

• Ozempic 1.0 mg: approximately R3,200 - R4,200 per month (4 pens/month at maintenance)
• Ozempic 2.0 mg: approximately R4,500 - R5,500 per month
• Wegovy 2.4 mg: approximately R4,500 - R6,500 per month (when available)

Prices vary between pharmacies. Dis-Chem, Clicks, and independent pharmacies all stock semaglutide products, but call ahead — Wegovy in particular can be out of stock for weeks at a time. Generic semaglutide options are emerging in SA and may offer savings of 30-50%, though availability is still patchy.

Medical Aid Coverage

This is where the regulatory label matters most:

• Ozempic for diabetes: Most medical aid plans cover Ozempic if you have a confirmed type 2 diabetes diagnosis (ICD-10 code E11). Some plans require a motivation letter from your doctor.
• Ozempic for weight loss (off-label): Generally NOT covered. You pay cash.
• Wegovy for weight loss: A growing number of comprehensive plans cover Wegovy if you meet BMI criteria (typically BMI ≥ 30, or BMI ≥ 27 with a weight-related comorbidity). Check your plan's formulary.

If you have type 2 diabetes AND want to lose weight, Ozempic may be the better financial choice because your medical aid is more likely to cover it. If your primary goal is weight loss without diabetes, Wegovy coverage depends entirely on your plan tier.

Weight Loss Results: How Do They Compare?

Clinical trial data gives us a good picture:

• Wegovy (STEP 1 trial): Participants lost an average of 14.9% of body weight over 68 weeks. For a 100 kg person, that is roughly 15 kg.
• Ozempic (SUSTAIN trials): Primarily studied for blood sugar, but weight loss of 4.5 - 6.5 kg was observed at 1.0 mg dose over 30-56 weeks. At the 2.0 mg dose, weight loss approached 8-10%.
• Real-world SA data: Anecdotally, South African patients on Ozempic 1.0 mg report 8-12 kg loss over 6 months. Wegovy patients at full dose report 12-18 kg over the same period.

The difference largely comes down to dose. If your doctor keeps you at Ozempic 1.0 mg, you will likely see less weight loss than if you titrate to Wegovy 2.4 mg. However, individual responses vary hugely — some people respond dramatically to lower doses.

Side Effects: Essentially the Same

Since the active ingredient is identical, the side effect profile is virtually the same for both products:

• Very common: Nausea (especially during titration), diarrhoea, constipation, reduced appetite
• Common: Headache, fatigue, abdominal pain, vomiting, bloating
• Less common: Gallstones (higher risk with rapid weight loss), injection site reactions
• Rare but serious: Pancreatitis, thyroid C-cell tumours (boxed warning — based on animal studies)

Wegovy's higher maximum dose may produce slightly more GI discomfort at the 2.4 mg level compared to Ozempic at 1.0 mg. The slower titration schedule is designed to offset this. Most patients find that nausea peaks during dose increases and settles within 2-3 weeks. Read our detailed semaglutide side effects guide for management strategies.

Who Should Choose Wegovy?

Wegovy may be the better fit if:

• Your primary goal is weight loss (not blood sugar control)
• You do NOT have type 2 diabetes
• Your BMI is 30+ (or 27+ with comorbidities like hypertension, sleep apnoea, or high cholesterol)
• Your medical aid covers Wegovy on its chronic formulary
• You want the highest available semaglutide dose (2.4 mg)
• You are committed to the full 16-week titration

Who Should Choose Ozempic?

Ozempic may suit you better if:

• You have type 2 diabetes and weight loss is a secondary benefit
• Your medical aid covers Ozempic for diabetes but not Wegovy
• Wegovy is out of stock in your area (still common in parts of SA)
• You respond well to a lower dose (0.5 - 1.0 mg) and do not need the 2.4 mg ceiling
• Cost is a major factor — Ozempic at 1.0 mg is the most affordable semaglutide option

Can You Switch Between Wegovy and Ozempic?

Yes — since the active ingredient is the same, switching is straightforward. Your doctor will match your current dose and adjust from there. Common scenarios in South Africa:

• Ozempic to Wegovy: If you have been on Ozempic 1.0 mg for weight loss and want a higher dose, your doctor may switch you to Wegovy and continue titrating up to 2.4 mg.
• Wegovy to Ozempic: If Wegovy stock runs out (it happens), you can switch to Ozempic at an equivalent dose to maintain your progress.

Never switch or adjust your dose without your prescribing doctor's guidance. The titration schedules exist to keep you safe.

What About Rybelsus?

There is a third semaglutide option: Rybelsus — an oral tablet (no injection). Rybelsus is approved for type 2 diabetes in South Africa at doses up to 14 mg daily. It is NOT currently approved for weight loss, and the oral bioavailability is lower than injectable forms. If you cannot tolerate injections, ask your doctor about Rybelsus, but be aware that weight loss results are typically more modest.

Other Alternatives to Consider

If neither Wegovy nor Ozempic is right for you — whether due to cost, availability, or side effects — South Africa has other options:

• Saxenda (liraglutide): A daily GLP-1 injection approved for weight loss. Less potent than semaglutide but well-established. See our Saxenda vs Ozempic comparison.
• Mounjaro (tirzepatide): A dual GIP/GLP-1 agonist showing even greater weight loss in trials. Limited SA availability in 2026 but worth watching.
• Generic semaglutide: Emerging options from local and international manufacturers at lower cost.

The Bottom Line

Wegovy and Ozempic are the same drug at different doses with different labels. If weight loss is your goal and you can access it, Wegovy at 2.4 mg offers the strongest clinical evidence for fat reduction. If you have diabetes, need medical aid coverage, or find Wegovy out of stock, Ozempic is an effective alternative that still delivers meaningful weight loss.

Either way, semaglutide works best combined with a calorie-controlled eating plan, regular physical activity, and ongoing medical supervision. The injection is a tool — not a shortcut.